Seroatlas · Human Serome Atlas

NAT9

Alpha/beta-tubulin-N-acetyltransferase 9

Also known as: DKFZP564C103, NAT9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9BTE0
Gene: NAT9
Ensembl: ENSG00000109065
Chromosome: 17
Canonical length: 207 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm

OverviewNCBI Gene

Predicted to enable tubulin N-terminal-methionine acetyltransferase activity. Part of protein-containing complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

207 residues, UniProt reviewed canonical sequence.

>Q9BTE0|NAT9
     1  MRLNQNTLLL GKKVVLVPYT SEHVPSRYHE WMKSEELQRL TASEPLTLEQ EYAMQCSWQE
    61  DADKCTFIVL DAEKWQAQPG ATEESCMVGD VNLFLTDLED LTLGEIEVMI AEPSCRGKGL
   121  GTEAVLAMLS YGVTTLGLTK FEAKIGQGNE PSIRMFQKLH FEQVATSSVF QEVTLRLTVS
   181  ESEHQWLLEQ TSHVEEKPYR DGSAEPC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NAT9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.27
Highest tissue expression: 55 nTPM

Expression across tissuesHPA

Tissue

adrenal gland: 55 nTPM
ovary: 29 nTPM
liver: 29 nTPM
pituitary gland: 28 nTPM
prostate: 26 nTPM
kidney: 25 nTPM

Single-cell type

breast lactating cells: 70 nCPM
ovarian stromal cells: 40 nCPM
differentiating spermatogonia: 39 nCPM
adrenal cortex cells: 38 nCPM
esophageal basal cells: 37 nCPM
leydig cells: 36 nCPM

Immune cell

naive B-cell: 31 nTPM
naive CD4 T-cell: 29 nTPM
intermediate monocyte: 24 nTPM
naive CD8 T-cell: 21 nTPM
memory B-cell: 21 nTPM
basophil: 20 nTPM

Brain region

cerebral cortex: 20 nTPM
cerebellum: 20 nTPM
medulla oblongata: 19 nTPM
white matter: 19 nTPM
pons: 19 nTPM
choroid plexus: 18 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.24
gnomAD pLI: 0
gnomAD missense Z: 0.1
DepMap mean gene effect: 0.08
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

tubulin N-terminal-methionine acetyltransferase activity

Cellular components

protein-containing complex

Protein domainsUniProt · Pfam · InterPro

GNAT domain
Acyl-CoA N-acyltransferase
N-acetyltransferase 9-like
Acetyltransferase (GNAT) domain

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NAT9 as an antibody target. Whether an autoantibody or antibody against NAT9 could matter depends on whether native NAT9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NAT9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NAT9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...